medicines, such as Tocilizumab, that can be used for treating Covid-19 patients. A bench of Chief Justice Dipankar Datta and Justice G S Kulkarni said that in light of the shortage of Tocilizumab,
the government must tell the citizens about other locally- manufactured, cheaper, and widely-available drugs that can be used instead. The Government of India, having placed on record its stand that Itolizumab, Dexamethasone, and Methylprednisolone are equivalent and/or better than Tocilizumab, it is high time all-out efforts are made by it as well as the state to remove the incorrect public perception that has since been created that only Tocilizumab can treat the inflammatory burst conditions in Covid-19 patients, the high court said.
Avoid over-reliance on foreign drugs in COVID-19 treatment: HC
SECTIONS
Last Updated: May 08, 2021, 12:19 PM IST
Share
Synopsis
A bench of Chief Justice Dipankar Datta and Justice G S Kulkarni said that in light of the shortage of Tocilizumab, the government must tell the citizens about other locally- manufactured, cheaper, and widely-available drugs that can be used instead.
Stating that over-reliance on imported drugs must be avoided, the Bombay High Court has asked the Centre and the Maharashtra government to create awareness about suitable alternatives to foreign-manufactured medicines, such as Tocilizumab, that can be used for treating COVID-19 patients.
A bench of Chief Justice Dipankar Datta and Justice G S Kulkarni said that in light of the shortage of Tocilizumab, the government must tell the citizens about other locally- manufactured, cheaper, and widely-available drugs that can be used instead.
A view of Bombay High Court. File
| Photo Credit:
VIVEK BENDRE
The Bench said that the government must tell the citizens about other locally-manufactured, cheaper and widely-available drugs that can be used instead. Stating that over-reliance on imported drugs must be avoided, the Bombay High Court has asked the Centre and the Maharashtra government to create awareness about suitable alternatives to foreign-manufactured medicines, such as Tocilizumab, that can be used for treating COVID-19 patients.
A Bench of Chief Justice Dipankar Datta and Justice G. S. Kulkarni said that in light of the shortage of Tocilizumab, the government must tell the citizens about other locally- manufactured, cheaper and widely-available drugs that can be used instead.
Stating that over-reliance on imported drugs must be avoided, the Bombay High Court has asked the Centre and the Maharashtra government to create awareness about suitable alternatives to foreign-manufactured medicines, such as Tocilizumab, that can be used for treating COVID-19 patients. A bench of Chief Justice Dipankar Datta and Justice G S Kulkarni said that in light of the shortage of Tocilizumab, the government must tell the citizens about other locally- manufactured, cheaper, and widely-available drugs that can be used instead. The Government of India, having placed on record its stand that Itolizumab, Dexamethasone, and Methylprednisolone are equivalent and/or better than Tocilizumab, it is high time all-out efforts are made by it as well as the state to remove the incorrect public perception that has since been created that only Tocilizumab can treat the inflammatory burst conditions in COVID-19 patients, the high court said.